5:31 PM
 | 
Nov 20, 2012
 |  BC Extra  |  Company News

FDA approves Novartis' Flucelvax

FDA approved seasonal influenza vaccine Flucelvax from Novartis AG (NYSE:NVS; SIX:NOVN) to prevent influenza subtypes A and type B in adults. Flucelvax is the first seasonal...

Read the full 112 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >